Innovent’s Triple Breakthrough Play: IBI363 Just Became the Most Dangerous Asset in Immuno-Oncology’s Coldest Corner
Innovent's IBI363 scores its third NMPA Breakthrough Therapy Designation—this time for MSS/pMMR colorectal cancer, the tumor type that killed...